Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal inflammatory disease that poses a heavy burden to the global healthcare system. However, the current paucity of mechanistic understanding of IBD pathogenesis hampers the development of aetiology-directed therapies. Novel therapeutic options based on IBD pathogenesis are urgently needed for attaining better long-term prognosis for IBD patients. The tripartite motif (TRIM) family is a large protein family including more than 70 structurally conservative members, typically characterized by their RBCC structure, which primarily function as E3 ubiquitin ligases in post-translational modification. They have emerged as regulators of a broad range of cellular mechanisms, including proliferation, differentiation, transcription and immune regulation. TRIM family proteins are involved in multiple diseases, such as viral infection, cancer and autoimmune disorders, including inflammatory bowel disease. This review provides a comprehensive perspective on TRIM proteins' involvement in the pathophysiology and progression of IBD, in particular, on intestinal mucosal barriers, gene susceptibility and opportunistic infections, thus providing novel therapeutic targets for this complicated disease. However, the exact mechanisms of TRIM proteins in IBD pathogenesis and IBD-related carcinogenesis are still unknown, and more studies are warranted to explore potential therapeutic targets of TRIM proteins in IBD.
Background The incidence of thyroid cancer is increasing every year. Surgical resection is one of the main treatments for thyroid cancer, but it can affect thyroid function. In women of childbearing age, thyroid dysfunction is associated with infertility. The aim of this study was to investigate the changes in fertility and the risk of adverse outcomes in women with thyroid cancer (post-thyroidectomy) combined with infertility. Methods This retrospective cohort study included 17086 in vitro fertilization (IVF) cycles from January 2014 to March 2022 at the Sun Yat-Sen Memorial Hospital Reproductive Center, Sun Yat-Sen University. A 1:4 propensity score matching was used to match the thyroid cancer group with the control group. Categorical variables were tested with chi-square test and continuous variables with Kruskal test to analyze the differences in baseline characteristics, thyroid stimulating hormone (TSH), number of mature follicles, number of eggs gained, normal fertilization rate, quality embryo rate and pregnancy outcome between the two groups. Generalized estimating equation was used to investigate the effects of TSH on clinical pregnancy and live birth in the two groups. Results The thyroid cancer group had significantly lower TSH levels than the control group (median: 1.27 mIU/L vs. 1.58 mIU/L, P = 0.017). However, the number of retrieved oocytes, normal fertilization rate, good quality embryo rate, clinical pregnancy rate, and live birth rate were not significantly different between the two groups (P > 0.05). History of thyroid cancer and TSH have an interactive effect on live birth rate (RR: 2.280, 95%CI: 1.126, 4.616, P = 0.022), but not clinical pregnancy rate (P < 0.05). Conclusions Our study showed that IVF-ET outcomes in infertile women were not affected by the history of thyroid cancer (post-thyroidectomy), but the live birth rates were more affected by TSH level. The thyroid function of patients with a history of thyroid cancer should be checked regularly and remained at a normal range. Trial registration This study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (SYSKY-2022-082-01)
Background The impact of smooth endoplasmic reticulum aggregates (SERa) on assisted reproductive technology (ART) outcomes was still controversial. Our objective is to investigate the impact of the presence of SERa on intracytoplasmic sperm injection (ICSI) outcomes. Methods This was a retrospective cohort study. A total of 1,090 fresh ICSI cycles from 944 patients between January 2016 and June 2020 were included. Outcomes from clinical, embryological and neonatal aspects were compared between SERa + and SERa- cycles as well as between SERa + and SERa- oocytes. Results The total gonadotropin (Gn) dose, number of oocytes retrieved, serum estradiol concentration and number of the available embryo were significantly higher in SERa + cycles than in SERa- cycles (P < 0.05). Comparable two pronuclei (2PN) fertilization rate and poly-pronucleus zygote rate were shown in SERa + and SERa- cycles (P > 0.05), but which were higher in SERa + oocytes than in SERa- oocytes (P < 0.05). No statistical difference in blastocyst formation rate was found in SERa + and SERa- cycles as well as in SERa + and SERa- oocytes (P > 0.05). Good-quality embryo rate was statistically higher in SERa- cycles than in SERa + cycles (P < 0.05), but the difference was comparable between SERa + and SERa- oocytes (P > 0.05). No statistical difference in clinical pregnancy rate, spontaneous abortion rate, live birth rate and premature delivery rate were found in SERa + and SERa- cycles as well as in SERa + and SERa- oocytes (P > 0.05). The implantation rate was comparable in SERa + and SERa- cycles (P > 0.05), but it is higher in the group of only SERa- embryo transfer when compared with the group of mixed SERa + and SERa- embryo transfer (P < 0.05). 159 newborns in SERa + cycles and 140 newborns in SERa- cycles were followed up. Comparable newborn malformation rate was observed between SERa + and SERa- cycles and oocytes (P > 0.05). Logistic regression analysis revealed number of oocytes and total dose of Gn were risk factors for SERa occurrence (aOR = 1.05 and 1.55, P < 0.001). Conclusion Oocyte's SERa is correlated with a number of oocytes retrieved and higher Gn dose, but it does not affect pregnancy outcomes and increase newborn malformation rate.
Background: The impact of SERa on ART outcomes was still controversial. Our objective is to investigate the impact of the presence of smooth endoplasmic reticulum aggregates (SERa) on ICSI outcomes. Methods: This was a retrospective cohort study. A total of 1,090 fresh ICSI cycles from 944 patients between January 2016 and June 2020 were included. Outcomes from clinical, embryological and neonatal aspects were compared between SERa+ and SERa- cycles as well as between SERa+ and SERa- oocytes. Results: The total gonadotropin (Gn) dose, number of oocytes retrieved, serum estradiol concentration and number of the available embryo were significantly higher in SERa+ cycles than in SERa- cycles (P<0.05). Comparable two pronuclei (2PN) fertilization rate and poly-pronucleus zygote rate were shown in SERa+ and SERa- cycles (P>0.05), but which were higher in SERa+ oocytes than in SERa- oocytes (P<0.05). No statistical difference in blastocyst formation rate was found in SERa+ and SERa- cycles as well as in SERa+ and SERa- oocytes (P>0.05). Good-quality embryo rate was statistically higher in SERa- cycles than in SERa+ cycles (P<0.05), but the difference was comparable between SERa+ and SERa- oocytes (P>0.05). No statistical difference in pregnancy rate, clinical pregnancy rate, spontaneous abortion rate, live birth rate and premature delivery rate were found in SERa+ and SERa- cycles as well as in SERa+ and SERa- oocytes (P>0.05). The implantation rate was comparable in SERa+ and SERa- cycles (P>0.05), but it is higher in the group of only SERa- embryo transfer when compared with the group of mixed SERa+ and SERa- embryo transfer (P<0.05). One hundred and fifty-nine newborns in SERa+ cycles and 140 newborns in SERa- cycles were followed up. Comparable newborn malformation rate was observed between SERa+ and SERa- cycles and oocytes (P>0.05). Logistic regression analysis revealed number of oocytes and total dose of Gn were risk factors for SERa occurrence (aOR=1.05 and 1.55, P<0.001).Conclusion: Oocyte's SERa is correlated with a number of oocytes retrieved and higher Gn dose, but it does not impact pregnancy outcomes and increase newborn malformation rate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.